Stenlf K, Cefalu WT, Kim KA, et al
SURMOUNT-4 showed that patients who discontinued tirzepatide after 36 weeks of treatment regained 14.8% of body weight over the subsequent 52 weeks, compared with continued weight loss of 5.5% in those who maintained the drug
T.UcanU.BoyaciogluM.IpekE.et al (2017)
Meanwhile, dual agonists, which target and activate both the GLP-1 (Glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, and triple agonists (targeting the GLP-1+GIP+Glucagon receptors) are also showing promise
Our team can help assess whether the lifestyle changes implemented during your GLP-1 treatment, such as improved diet and increased physical activity, are sustainable independently
We observed that KRAS mutant cancer cell lines (HCT116 and H460) and MDA-MB-435, with a high GSTO1 expression, were sensitive to GSTO1 knockdown, but not MCF7 cells (Supplementary Fig